MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Avadel Pharmaceuticals plc Net Debt 2011-2026 | AVDL
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Avadel Pharmaceuticals plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -49.7 M | -28.5 M | -72.2 M | 92.6 M | 56.6 M | 166 M | 107 M | -16.3 M | -38.4 M | -63.9 M | 78.7 M | 78.9 M | 33.9 M | 259 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 166 M | -72.2 M | 24.6 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cronos Group
CRON
|
-1.07 B | $ 2.69 | 1.32 % | $ 1.42 B |  Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | USA |
 |
Canopy Growth Corporation
CGC
|
193 M | $ 1.25 | -3.02 % | $ 134 M | Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | USA |
 |
OrganiGram Holdings
OGI
|
90.7 M | $ 1.74 | 0.29 % | $ 402 M | Canada |
 |
Emergent BioSolutions
EBS
|
338 M | $ 12.94 | -3.14 % | $ 663 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | USA |
 |
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | USA |
 |
Zomedica Corp.
ZOM
|
-10.2 M | - | -0.21 % | $ 98 M | USA |
 |
Sundial Growers
SNDL
|
-28.4 M | $ 1.65 | 0.3 % | $ 3.37 M | Canada |
 |
Evolus
EOLS
|
36.3 M | $ 5.61 | -2.35 % | $ 348 M | USA |
 |
Harrow Health
HROW
|
173 M | $ 47.21 | -7.51 % | $ 1.54 B | USA |
 |
China Pharma Holdings
CPHI
|
-4.73 M | $ 1.29 | -4.79 % | $ 22.5 M |  China |
 |
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M | USA |
 |
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
21.1 B | $ 7.47 | -3.93 % | $ 2.73 B | Canada |
 |
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 4.78 | -1.04 % | $ 67.2 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-146 M | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
285 M | $ 4.25 | -0.47 % | $ 86.3 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-131 M | $ 4.17 | -1.07 % | $ 549 M | USA |
 |
Pacira BioSciences
PCRX
|
317 M | $ 23.67 | -9.03 % | $ 1.09 B | USA |
 |
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
-6.41 M | - | - | $ 5.07 M | USA |
 |
Perrigo Company plc
PRGO
|
3.05 B | $ 14.99 | 1.94 % | $ 2.06 B | USA |
 |
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
691 K | $ 0.94 | -3.6 % | $ 21.9 M | USA |
 |
Relmada Therapeutics
RLMD
|
-2.5 M | $ 4.27 | -3.61 % | $ 129 M | USA |
 |
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-34 M | $ 9.12 | -2.04 % | $ 648 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-5.29 M | $ 3.65 | -3.44 % | $ 4.53 M | USA |
 |
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-70.9 M | $ 5.25 | -1.22 % | $ 214 M | USA |
 |
SCYNEXIS
SCYX
|
-31.1 M | $ 0.67 | 0.42 % | $ 32.1 M | USA |
 |
Tilray
TLRY
|
14.4 M | $ 9.15 | 0.26 % | $ 5.65 B | Canada |
 |
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
3.68 M | $ 2.09 | 1.46 % | $ 21.8 M | USA |
 |
Veru
VERU
|
-20.9 M | $ 2.35 | 1.73 % | $ 317 M | USA |
 |
Viatris
VTRS
|
16.8 B | $ 12.74 | 1.07 % | $ 15.4 B | USA |